Clinical Trial Update: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol update assessing crizotinib for cancers with MET exon 14 deletions; results have been posted (2026-03-20).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumor

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-20